Rebound ab heute ?
Seite 1 von 6 Neuester Beitrag: 26.03.09 08:26 | ||||
| Eröffnet am: | 12.02.08 09:48 | von: plusquamperf. | Anzahl Beiträge: | 129 |
| Neuester Beitrag: | 26.03.09 08:26 | von: börsenanimat. | Leser gesamt: | 14.998 |
| Forum: | Hot-Stocks | Leser heute: | 1 | |
| Bewertet mit: |  | |||
| Seite: < | 2 | 3 | 4 | 5 | 6 6 > | ||||
auch positiv gestimmt
2008-02-11 09:00 ET - News Release
BOTHELL, Wash., Feb. 11 /PRNewswire-FirstCall/ -- In response to the recent comments by certain plaintiff law firms regarding their filing of class action lawsuits, CellCyte Genetics Corporation (the "Company") asserts that the pending claims are without merit and will be shown to be so in a court of law. To that end, CellCyte has retained the international law firm of Duane Morris LLP as its counsel and will defend itself vigorously in these matters. Concurrently, the Company will continue its commitment to and pursuit of its policy of ensuring that its operations comply with all applicable laws.
"CellCyte is founded on patented technology discovered by and licensed from the US Department of Veteran Affairs. We continue a solid and aggressive development plan for this important technology for the delivery of adult stem cells to the human heart," said Gary A. Reys, Chairman and CEO of CellCyte. "Our highly skilled management and scientific team are committed to developing our technologies to their fullest potential and we continue to be actively involved in collaborations with the Cleveland Clinic and other research leaders".
"Further," Reys said, "CellCyte is actively moving its intellectual properties through the US patent and Trademark office to insure that our technologies are well protected, which is one of the cornerstones of any biotechnology company which helps insure our shareholders a solid and protected technology base. Our most recent patent was issued in November 2007 that covers CellCyte's lead composition. This most recent patent milestone gives CellCyte three fully issued patents."
CellCyte Genetics continues to be actively engaged in carrying out its business plan and corporate objectives as stated in the company's literature and filings. This fact is further evidenced by such major advances as its move to the Company's new 26,000 foot facility and corporate offices in Bothell Washington and its continued business development efforts headed by Tony Colasin, who was previously Senior Director of Business Development at ICOS, which was recently acquired by Lilly.
About CellCyte Genetics
CellCyte Genetics, a Washington State company, is an emerging biotechnology company engaged in the principal business of the discovery, development and commercialization of breakthrough stem cell enabling therapeutic products for use in regenerative medicine. The Company also has a medical device division being developed to grow and expand a variety of cells including Islet cells for diabetes and eventually proteins.
For further information see: http://www.cellcyte.com.
Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.
Safe Harbor Statement
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD- LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH THE CLOSING OF THE SHARE EXCHANGE AGREEMENT AND THE DEVELOPMENT AND FUNDING OF THE COMPANY CONSEQUENT THEREON, AS WELL AS THE RISKS SHOWN IN THE COMPANY'S MOST RECENT ANNUAL REPORT ON FORM 10-KSB AND ON FORM 10-QSB AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL REQUIREMENTS AND THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY'S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS.
THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY'S PERIODIC REPORTS FILED FROM TIME-TO- TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS RELEASE. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
CellCyte Genetics Corporation
CONTACT: Investor Relations of CellCyte Genetics Corporation,
+1-425-368-1790
Web site: http://www.cellcyte.com/
denn die werden wohl nicht einfach tatenlos zusehen wie es nach oben geht
WKN: A0MLCV ISIN:US15116P1030 Branche: Land: USA
§
Times & Sales
Uhrzeit Kurs§letztes Volumen kumuliert
10:12:58 0,23 10.000 68.448 §
09:56:19 0,23 850 58.448 §
09:56:15 0,23 2.000 57.598 §
09:43:13 0,226 15.000 55.598 §
09:40:21 0,227 11.358 40.598 §
09:20:01 0,234 5.000 29.240 §
09:12:25 0,23 4.500 24.240 §
09:05:32 0,234 14.000 19.740 §
09:01:07 0,232 5.740§5.740
http://finance.yahoo.com/q?s=CCYG.OB
Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against CellCyte Genetics Corporation (OTCBB: CCYG)
Marketwire (Wed, Feb 6)
• REPEAT/Hagens Berman Sobol Shapiro Announces Proposed Class-Action Lawsuit Against CellCyte
Business Wire (Mon, Feb 4)
• Cohen, Milstein, Hausfeld & Toll, P.L.L.C. Announces Class Action Lawsuit on Behalf of Investors of CellCyte Genetics Corporation
Business Wire (Fri, Feb 1)
• CELLCYTE GENETICS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Tue, Jan 22)
• Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation
PR Newswire (Fri, Jan 18)
• CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
PR Newswire (Fri, Jan 18)
• Hagens Berman Sobol Shapiro Announces Proposed Class-Action Lawsuit Against CellCyte
Business Wire (Thu, Jan 17)
• Brower Piven Announces the Filing of a Class Action Lawsuit Against CellCyte Genetics Corporation
Marketwire (Thu, Jan 17)
• Hagens Berman Sobol Shapiro Announces Proposed Class-Action Lawsuit Against CellCyte
PR Newswire (Mon, Jan 14)
Optionen
| Boardmail an "nekro" |
Wertpapier: CellCyte Genetics |
ausserdem wird ja jetzt wieder der Kurs in den USA gemacht was die Deutschen
aber noch nicht mitbekommen haben